Right timing for transient elastography lead the right follow up after HCV treatment

Background: The improvement of liver fibrosis assessed using transient elastography (TE) by FibroScan® is leading to new insights in the concepts of fibrosis regression. The possibility of using new direct antiviral agents (DAA) in cirrhotic patients, previous excluded from PegInterferon treatment for risk of hepatic failure, has permitted to verify the hypothesis of fibrosis regression in these patients. TE should be interpreted taking into account the inflammatory profile associated with hepatitis.